Compare Abeona Therapeutics Inc (ABEO) vs Aptiv PLC (APTV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Aptiv PLC — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while Aptiv PLC trades at $56.89 (market cap $12.45B). The key difference: Aptiv PLC is far larger — about 33.3× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Aptiv PLC nearer its low. Which is the better fit depends on your goals.
| ABEO | APTV | |
|---|---|---|
Market Cap | $373.32M | $12.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $76.82 |
52-Week Low | $4.17 | $52.57 |
Enterprise Value | $228.22M | $19.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
APTV trades at $58.85, down 0.07% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.71, exceeding expectations of $1.62. Revenue for 2025 reached $20.40B with a net income margin of 1.77%. Analyst consensus is strongly bullish with a $80.67 price target, though technical indicators show selling pressure with support at $58.
The outlook remains mixed: strong analyst support and solid cash flow trends contrast with narrow profit margins and bearish technicals. Key risks include margin compression and high debt levels, but institutional sentiment suggests potential upside if earnings momentum continues through Q2 results on August 4, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Aptiv PLC
Aptiv's signal and power solutions segment supplies components and systems that make up a vehicle's electrical system backbone, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The advanced safety and user experience segment provides body controls, infotainment and connectivity systems, passive and active safety electronics, advanced driver-assist technologies, and displays, as well as the development of software for these systems. Aptiv's largest customer is General Motors at roughly 12% of 2021 revenue, including sales to GM's Shanghai joint venture, followed by Stellantis at 11%, and Volkswagen at 9%. North America and Europe represented approximately 38% and 33% of total 2019 revenue, respectively.
Read more on APTV →
